Literature DB >> 14609577

Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials.

Meixiao Long1, Amy D Higgins, Marianne A Mihalyo, Adam J Adler.   

Abstract

It has recently been shown that effector/memory T cells can undergo peripheral tolerization in response to self-antigen. In the present study, we found that within 24h self-antigen profoundly impairs the ability of CD4 effectors to express TNF-alpha (and to a lesser extent IFN-gamma); however, several days of self-antigen exposure is required to impair non-effector functions such as IL-2 expression and proliferation. Since only half of the initial effector CD4 cell population expresses effector cytokines following brief antigenic stimulation, tolerization might have been mediated either through functional inactivation of effector-competent cells, or alternatively by the selective deletion of competent and expansion of non-competent cells. When briefly stimulated effectors were fractionated based on their expression of IFN-gamma, the IFN-gamma(-) sub-population was able to express IFN-gamma following secondary stimulation, indicating that all effector CD4 cells are functionally competent. Furthermore, both IFN-gamma(+) and IFN-gamma(-) sub-populations underwent tolerization in response to self-HA (although the former was slightly more prone to deletion at later time points). Thus, effector CD4 cell tolerization is mediated primarily through the functional inactivation of effector-competent cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609577      PMCID: PMC2846335          DOI: 10.1016/j.cellimm.2003.08.008

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  34 in total

1.  CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement.

Authors:  Amy D Higgins; Marianne A Mihalyo; Patrick W McGary; Adam J Adler
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation.

Authors:  Patrick E Fields; Sean T Kim; Richard A Flavell
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

3.  T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes.

Authors:  Orly Avni; Dong Lee; Fernando Macian; Susanne J Szabo; Laurie H Glimcher; Anjana Rao
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

4.  Memory CD8(+) T cells undergo peripheral tolerance.

Authors:  Huub T C Kreuwel; Sandra Aung; Cheryl Silao; Linda A Sherman
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

Review 5.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

6.  Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.

Authors:  H Winter; H M Hu; K McClain; W J Urba; B A Fox
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Analysis of the relationship between viral infection and autoimmune disease.

Authors:  V Panoutsakopoulou; M E Sanchirico; K M Huster; M Jansson; F Granucci; D J Shim; K W Wucherpfennig; H Cantor
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

8.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

9.  The temporal importance of TNFalpha expression in the development of diabetes.

Authors:  E A Green; R A Flavell
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

10.  Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes.

Authors:  S Seewaldt; H E Thomas; M Ejrnaes; U Christen; T Wolfe; E Rodrigo; B Coon; B Michelsen; T W Kay; M G von Herrath
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

View more
  12 in total

1.  Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.

Authors:  Amy D H Doody; Joseph T Kovalchin; Marianne A Mihalyo; Adam T Hagymasi; Charles G Drake; Adam J Adler
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.

Authors:  Meixiao Long; Aaron M Slaiby; Adam T Hagymasi; Marianne A Mihalyo; Alexander C Lichtler; Steven L Reiner; Adam J Adler
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

3.  Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen.

Authors:  Richard Verbeek; Koen van der Mark; Eric F Wawrousek; Arianne C Plomp; Johannes M van Noort
Journal:  Immunology       Date:  2007-04-26       Impact factor: 7.397

4.  Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

Authors:  Marianne A Mihalyo; Adam T Hagymasi; Aaron M Slaiby; Erin E Nevius; Adam J Adler
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

5.  Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.

Authors:  Adam T Hagymasi; Aaron M Slaiby; Marianne A Mihalyo; Harry Z Qui; David J Zammit; Leo Lefrancois; Adam J Adler
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

6.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Authors:  Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

7.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Antibodies generated against conserved antigens expressed by bacteria and allergen-bearing fungi suppress airway disease.

Authors:  Nicholas W Kin; Emily K Stefanov; Brian L P Dizon; John F Kearney
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

9.  Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen.

Authors:  Meixiao Long; Aaron M Slaiby; Shuang Wu; Adam T Hagymasi; Marianne A Mihalyo; Suman Bandyopadhyay; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

10.  The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells.

Authors:  Marie-Clare St Rose; Harry Z Qui; Suman Bandyopadhyay; Marianne A Mihalyo; Adam T Hagymasi; Robert B Clark; Adam J Adler
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.